Research programme: innate immune system modulation therapeutics - Cypralis Limited
Alternative Names: Modulation of innate immune system - Cypralis LimitedLatest Information Update: 07 Jan 2022
At a glance
- Originator Cypralis Limited
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Unspecified
Most Recent Events
- 07 Jan 2022 Innate immune system modulation therapeutics - Cypralis Limited is available for licensing as of 07 Jan 2022. http://www.cypralis.com/business-development/investors
- 03 Jan 2022 Early research in Unspecified in United Kingdom (unspecified route) (Cypralis Limited pipeline, January 2022)